Monepantel

NeuroSense's PrimeC demonstrated significant benefits in ALS treatment during a Phase 2b clinical trial, extending complication-free survival by 53% compared to placebo. The therapy also showed improvements in patients' quality of life, leading to discussions with U.S. regulators about Phase 3 trials and potential early approval in Canada.

Neurizon has submitted an Investigational New Drug (IND) application to the FDA for NUZ-001, a drug targeting TDP-43 protein aggregation in ALS.

The HEALEY ALS Platform Trial is pioneering a new approach to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS).

The EMA has recommended orphan medicinal product designation for NUZ-001 (monepantel) for treating amyotrophic lateral sclerosis (ALS).

Neurizon Therapeutics has received a positive opinion from the EMA for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis.